SCHEMBL16085054

SCHEMBL16085054

Cc1ccc(CCCCN)cc1C#Cc1cnc2cccnn12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.52
RIPK2 O43353 2/20 0.52
RIPK3 Q9Y572 2/20 0.52
ABL1 P00519 14/20 0.49
CSF1R P07333 2/20 0.49
ROR1 Q01973 3/20 0.47
CYP3A4 P08684 2/20 0.42
KCNH2 Q12809 2/20 0.42
ABL2 P42684 2/20 0.41
GAK O14976 1/20 0.41
MLNR O43193 1/20 0.41
JAK2 O60674 1/20 0.41
NR1I2 O75469 1/20 0.41
ABCB11 O95342 1/20 0.41
MAP4K4 O95819 1/20 0.41
EGFR P00533 1/20 0.41
NR3C1 P04150 1/20 0.41
ERBB2 P04626 1/20 0.41
NTRK1 P04629 1/20 0.41
LCK P06239 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17471706 0.90 RIPK1 (0.52) RIPK1RIPK2RIPK3ABL1CSF1R
SCHEMBL17471701 0.90 RIPK1 (0.52) RIPK1RIPK2RIPK3ABL1CSF1R
SCHEMBL17471724 0.89 RIPK1 (0.52) RIPK1RIPK2RIPK3ABL1CSF1R
SCHEMBL17471732 0.81 ABL1 (0.46) RIPK1RIPK2RIPK3ABL1CSF1R
SCHEMBL17471734 0.81 ABL1 (0.46) RIPK1RIPK2RIPK3ABL1CSF1R
SCHEMBL14705592 0.80 CSF1R (0.55) ABL1CSF1RROR1CYP3A4KCNH2
SCHEMBL17471717 0.78 CSF1R (0.57) ABL1CSF1RROR1CYP3A4KCNH2
SCHEMBL17471729 0.76 CSF1R (0.56) RIPK1RIPK2RIPK3ABL1CSF1R
SCHEMBL22243490 0.75 CSF1R (0.66) ABL1CSF1RROR1CYP3A4KCNH2
SCHEMBL15096062 0.74 ROR1 (0.67) RIPK1RIPK2RIPK3ABL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014145022-A1 HYBRID NECROPTOSIS INHIBITORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-09-18 WO disclosed